Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
87 hedge funds and large institutions have $107M invested in Antares Pharma, Inc. in 2014 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 33 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
40% more capital invested
Capital invested by funds: $76.7M → $107M (+$30.7M)
6% more funds holding
Funds holding: 82 → 87 (+5)
39% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 33
97% less call options, than puts
Call options by funds: $9K | Put options by funds: $291K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$2.25M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$965K |
| 3 |
DM
Deerfield Management
New York
|
+$631K |
| 4 |
B
Baird
Milwaukee,
Wisconsin
|
+$566K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$399K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.74M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$2.01M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$555K |
| 4 |
WHI
William Harris Investors
Chicago,
Illinois
|
-$444K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$224K |
ATRS Hedge Fund Activity: Q4 2014 in Review
87 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2014, worth a combined $107M — up 40% from $76.7M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ATRS positions and 9 closed out — a net gain of 7 holders — while 20 added to existing stakes and 33 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $2.25M. The largest seller was Millennium Management, cutting an estimated $6.74M.
- 87 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2014, up from 82 in Q3 2014.
- Funds reported $107M of Antares Pharma, Inc. stock for Q4 2014, up 40% quarter-over-quarter.
- 16 funds opened new Antares Pharma, Inc. positions in Q4 2014 and 9 closed out, a net change of +7 holders.
- The largest Antares Pharma, Inc. buyer in Q4 2014 was Broadfin Capital, an estimated $2.25M added.
- The largest Antares Pharma, Inc. seller in Q4 2014 was Millennium Management, an estimated $6.74M sold.
Based on aggregated 13F filings for Q4 2014.